Joint examination of reflexive vertical saccades and small involuntary fixational saccades improves the classification of patients with progressive supranuclear palsy (PSP): a ROC study.

A slowing of saccadic eye movements is one of the key symptoms of progressive supranuclear palsy and therefore represents a core functional domain of the current diagnostic criteria. However, there is considerable overlap between the saccade velocities of healthy people and patients in early stages. Therefore, a highly specific discrimination between patients and controls based on eye velocity often results in a considerable loss of sensitivity.

A network perspective on cognition in individuals with Parkinson's disease.

Introduction: In neuropsychological diagnostics, the assignment of cognitive tests to domains is usually not empirically based. Hence, we aimed to assess the dimensionality structure of cognition in individuals with Parkinson's disease (PD) and conceptually replicate the findings in cognitively healthy individuals (CHIs).

Methods: We performed Exploratory Graph Analysis (EGA) for dimensionality analysis of cognitive test scores in = 698 individuals with PD from the DEMPARK/LANDSCAPE study.

Early-onset sleep alterations found in patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse models.

Sleep alterations have been described in several neurodegenerative diseases yet are currently poorly characterized in amyotrophic lateral sclerosis (ALS). This study investigates sleep macroarchitecture and related hypothalamic signaling disruptions in ALS. Using polysomnography, we found that both patients with ALS as well as asymptomatic and mutation carriers exhibited increased wakefulness and reduced non-rapid eye movement sleep.

A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy.

Background: Patients with Progressive Supranuclear Palsy (PSP) suffer from several neuropsychological impairments. These mainly affect the frontal lobe and subcortical brain structures. However, a scale for the assessment of cognitive and neuropsychiatric disability in PSP is still missing.

Sub-Microliter H Magnetic Resonance Spectroscopy for In Vivo High-Spatial Resolution Metabolite Quantification in the Mouse Brain.

Proton magnetic resonance spectroscopy (MRS) offers a non-invasive, repeatable, and reproducible method for in vivo metabolite profiling of the brain and other tissues. However, metabolite fingerprinting by MRS requires high signal-to-noise ratios for accurate metabolite quantification, which has traditionally been limited to large volumes of interest, compromising spatial fidelity. In this study, we introduce a new optimized pipeline that combines LASER MRS acquisition at 11.